Compare iShares MSCI France ETF (EWQ) vs Merck & Co., Inc. (MRK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares MSCI France ETF vs Merck & Co., Inc. — how do they compare? iShares MSCI France ETF trades at $41.49 (market cap $330.91M), while Merck & Co., Inc. trades at $146.31 (market cap $351.28B). The key difference: Merck & Co., Inc. is far larger — about 1061.6× iShares MSCI France ETF's market cap, and Merck & Co., Inc. pays a 2.39% dividend while iShares MSCI France ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold iShares MSCI France ETF for 55 Days and Merck & Co., Inc. for 98 Days on average.
| EWQ | MRK | |
|---|---|---|
Market Cap | $330.91M | $351.28B |
Volume | 556,654 | 7,969,665 |
Sector | Broad Market / Factor | Health |
52-Week High | $48.35 | $156.43 |
52-Week Low | $41.32 | $82.49 |
Typical Hold Time | 55 Days | 98 Days |
Enterprise Value | — | $398.04B |
Dividend Yield | — | 2.39% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
EWQ is currently trading at $41.34, down 1.12% on the day, with technical indicators showing a bearish trend despite oversold RSI readings. The stock faces significant technical pressure with moving averages signaling strong selling momentum. Recent news highlights European market volatility driven by ECB rate hikes and energy price inflation, creating headwinds for European-focused investments.
The outlook remains cautious as monetary tightening and geopolitical risks weigh on European equities. Key support sits at $41 with resistance at $42, while oversold conditions suggest potential for near-term stabilization. However, sustained recovery depends on easing inflation pressures and improved eurozone economic sentiment.
Merck (MRK) trades at $144.96, up 1.52% today, with a bearish technical signal despite recent earnings beats. The stock shows strong profitability with a 72.97% gross margin and 28.07% net income margin for 2025, though its P/E ratio of 113.9 indicates high valuation. Recent news highlights Merck's acquisition of Terns Pharmaceuticals to bolster its oncology pipeline, reflecting strategic growth initiatives amid competitive pressures.
The outlook is mixed: analyst consensus is bullish with a $158.78 price target, but technical indicators and a high P/E suggest near-term caution. Key risks include integration challenges from acquisitions and macroeconomic headwinds affecting pharmaceutical R&D investment. Revenue growth and pipeline execution remain critical for sustained upside.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About iShares MSCI France ETF
EWQ is a country-specific ETF that tracks the performance of the French equity market. It provides exposure to major global brands across sectors like luxury goods, industrials, and healthcare, including LVMH, Schneider Electric, and Hermes.
Read more on EWQ →About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →
